More realistic forecasting of future life events after psilocybin for treatment-resistant depression

Participant characteristics indicated a predominantly Caucasian sample (93.33%), mostly male (73.33%) and with post-secondary education (80%). At baseline, TRD patients had markedly higher depressive symptom scores on the BDI than controls (patients: M = 34.33, SD = 7.44; controls: M = 3.67, SD = 3.83; p < 0.001, g = 5.0). Patients showed a large and statistically significant reduction in BDI score one week after the second psilocybin session (post-treatment M = 12.13, SD = 9.80) compared with baseline [t(14) = 7.900, p < 0.001; 95% CI (16.17, 28.23), g = 1.9]. No significant BDI change occurred in controls over the same period. Temporal assessment across dosing days showed that BDI scores did not decline naturally prior to treatment (no difference between baseline and dosing day 1), but were significantly reduced by dosing day 2 compared with baseline and dosing day 1. Scores fell further one week after both sessions, indicating progressive improvement following each dose. On the forecasting task at baseline, patients estimated similar probabilities for desirable (M = 0.29, SD = 0.15) and undesirable (M = 0.23, SD = 0.15) events, yet reported experiencing significantly more desirable (M = 4.60, SD = 1.76) than undesirable events (M = 1.40, SD = 1.35) in the ensuing 30 days [t(14) = 5.967, p < 0.001, g = 1.5]. By contrast, controls predicted markedly higher likelihoods for desirable than undesirable events at baseline (desirable M = 0.57, SD = 0.09) and their experienced event counts matched their expectations. Between-group comparisons showed that patients predicted significantly fewer desirable events than controls at baseline [t(28) = 5.820, p < 0.001, g = 2.2], despite similar actual event rates across groups during that period. After psilocybin treatment, patients' predictions shifted: they gave higher probabilities for desirable (M = 0.44, SD = 0.20) than undesirable events and reported more desirable events actually occurring in the subsequent 30 days. Forecasting accuracy increased significantly in patients post-treatment (pre M = 0.71, SD = 0.12; post M = 0.76, SD = 0.07; t(14) = 1.857, p = 0.042, g = 0.6), whereas controls showed no significant change in accuracy between baseline and repeat assessment. There were no significant between-group differences in accuracy at baseline or follow-up. Bias scores confirmed a baseline pessimism in patients (mean bias M = -0.10, SD = 0.12), significantly below zero [t(14) = -3.260, p = 0.006, g = 1.1]. Following treatment the mean bias shifted to near zero (M = 0.02, SD = 0.08), a significant reduction in pessimism [t(14) = -2.714, p = 0.017, g = 0.7], and no longer differed from zero. Controls showed negligible bias at both time points. Correlational analyses indicated that greater baseline pessimism was associated with more severe depressive symptoms among patients (Spearman rs = -0.55, p = 0.017). Change scores showed that reductions in BDI were significantly related to reductions in pessimism for patients (r = -0.57, p = 0.014).

Serafini and colleagues interpret their findings as evidence that the combination of psilocybin and psychological support alleviated an unjustified pessimism bias in patients with TRD, and that this cognitive change occurred in parallel with marked reductions in depressive symptoms. The investigators note that patients were excessively pessimistic at baseline relative to their actual life circumstances, and that after treatment they made more accurate forecasts that resembled the behaviour of healthy controls. The authors situate these results within prior psychedelic research showing rapid antidepressant effects and enduring increases in optimism and wellbeing following single doses of classic psychedelics. Potential neurobiological mechanisms discussed include engagement of the 5-HT2A receptor, temporary disruption and subsequent reintegration of the default mode network, and a proposed "reset" or plasticity-enhancing state that may permit revision of entrenched cognitive biases in an enriched therapeutic context. The discussion also acknowledges that optimism and pessimism can each have adaptive functions, and argues for a balanced, reality-focused perspective as optimal for mental health. Key strengths highlighted by the study team are the use of an objective, behavioural measure (the POFLE) rather than only subjective self-report, and the focus on a cognitive facet of the depressive triad that can be prospectively validated against actual events. At the same time, the authors emphasise several limitations: the open-label design, small sample size, and the fact that control subjects did not undergo the same treatment procedures (so non-pharmacological components of the intervention, such as psychological support, cannot be ruled out). They also acknowledge the cross-sectional nature of the follow-up interval reported here, the inability to fully exclude natural symptom decline, and the unresolved question of causality—whether cognitive-bias change is a direct effect of psilocybin or an epiphenomenon of mood improvement. Finally, the investigators propose that a common mediating factor may underlie both symptom change and bias change and recommend further controlled, prospective studies—ideally incorporating neuroimaging paradigms that probe prospection—to clarify mechanisms, specificity and durability of the effects reported here.

The study concludes that psilocybin administered with psychological support was associated with alleviation of pessimism bias and large reductions in depressive symptoms in a small sample of TRD patients, as measured behaviourally by the POFLE task. The authors state that this is the first behavioural demonstration of psychedelic-induced change in a cognitive bias integral to depression and call for further controlled research to establish causality, reliability, specificity and the durability of these findings.